Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: Findings from the ALOHA study

Pharmacotherapy

Volumn 28, Issue 3, 2008, Pages 314-322

  Cohen, Calvin J ^a   Kubota, Marshall ^b   Brachman, Philip S ^c   Harley, William B ^d   Schneider, Stefan ^e   Williams, Vanessa C ^f   Sutherland Phillips, Denise H ^f   Lim, Michael L ^g   Balu, Rukmini B ^f   Shaefer, Mark S ^f,h  

^a HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ID Associates   (United States)

^e ST MARY MEDICAL CENTER   (United States)

^f GLAXOSMITHKLINE   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

^h NONE   (United States)

Author keywords

Abacavir hypersensitivity reaction; Abacavir lamivudine; Antiretroviral therapy; Safety; Tolerability

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR PHOSPHATE; ATAZANAVIR; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; VIRAL LOAD;

EID: 40149097939     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.3.314     Document Type: Article

References (29)

1. Willemot P, Klein MB. Prevention of HIV-associated opportunistic infections and diseases in the age of highly active antiretroviral therapy. Expert Rev Anti Infect Ther 2004;2:521-32.
2. Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007;21:685-92.
3. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006;20:223-31.
4. Carrieri MP, Leport C, Protopopescu C, et al. Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr 2006;41:477-85.
5. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003;17:169-77.
6. Wu H, Huang Y, Acosta EP, et al. Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr 2005;39:272-83.
7. Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. October 10, 2006:1-113. Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentsGL.pdf. Accessed September 11, 2007.
8. Clotet B, Carmena J, Pulido F, Luque I, Rodriguez-Alcantara F. Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine and abacavir on antiretroviral-experienced patients. HIV Clin Trials 2004;5:33-9.
9. Dando TM, Scott LJ. Abacavir plus lamivudine: a review of their combined use in the management of HIV infection. Drugs 2005;65:285-302.
10. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004,39:1038-46.
11. Moyle GJ, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen once daily in antiretroviral combination study. J Acquir Immune Defic Syndr 2005;38:417-25.
12. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005;192: 1921-30.
13. Bartlett JA, Johnson J, Herrera G, et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir or stavudine. J Acquir Immune Defic Syndr 2006;43:284-92.
14. Anderson AML, Bartlett JA. Fixed-dose combination abacavir/lamivudine in the treatment of HIV-1 infection. Expert Rev Anti Infect Ther 2005;3:871-83.
15. Goedken AM, Herman RA. Once-daily abacavir in place of twice-daily administration. Ann Pharmacother 2005;39:1302-8.
16. Division of AIDS, National Institute of Allergy and Infectious Diseases. Division of AIDS table for grading severity of adult adverse experiences. Rockville, MD: National Institute of Allergy and Infectious Diseases, 1992.
17. Anonymous. E2A: clinical safety data management: definitions and standards for expedited reporting. Federal Register 1995;60:11284-7.
18. Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Qual Life Res 2001;10:517-31.
19. Woodcock A, Bradley C. Validation of the revised 10-item HIV treatment satisfaction questionnaire status version and new change version. Value Health 2006;9:320-33.
20. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006;368:467-82. (Erratum in Lancet 2006;368:1238.)
21. Wit FW, Wood R, Horban A, et al. Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. AIDS 2001;15:2423-9.
22. Martin A, Nolan D, Almeida CA, Rauch A, Mallal S. Predicting and diagnosing abacavir and nevirapine hypersensitivity: from bedside to bench and back again. Pharmacogenomics 2006;7:15-23.
23. Munderi P, for the DART Trial Team. Safety of nevirapine compared to abacavir on a background of zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial [abstract]. In: Program and abstracts of the 13th conference on retroviruses and opportunistic infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2006: abstract 109LB.
24. Brothers C, Cutrell A, Zhao H, at al. Once daily administration of abacavir is not a clinical risk factor for suspected hypersensitivity reactions in clinical trials and rash alone is not sufficient to diagnose the reaction [abstract]. In: Program and abstracts of the 12th conference on retroviruses and opportunistic infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2005: abstract 386.
25. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004;5:203-11.
26. Saag M, Balu R, Brachman P, et al. High sensitivity of HLA-B*5701 in immunologically confirmed cases of abacavir hypersensitivity in white and black patients. Clin Infect Dis, in press.
27. Mallal S, Phillips E, Carosi G, et al. PREDICT-1: a novel randomized prospective study to determine the clinical utility of HLA-B*5701 screening to reduce abacavir hypersensitivity in HIV-1 infected subjects (study CNA106030). Presented at the 4th International AIDS Society conference on HIV pathogenesis, treatment, and prevention, Sydney, Australia, July 22-25, 2007. Available from www.ias2007.org/pag/ppt/WESS101.ppt. Accessed September 21, 2007.
28. Sosa N, Hill-Zabala C, Dejesus E, et al. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). J Acquir Immune Defic Syndr 2005;40:422-7.
29. Lamarca A, Clumeck N, Plettenberg A, et al. Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL3000I study). J Acquir Immune Defic Syndr 2006;41:598-606.